Overview

Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Status:
Not yet recruiting

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

TRIPLET HCC is a phase II-III trial that assess the effectivness of addition of ipilimumab to the combination atézolizumab-bévacizumab, on global survival and response to the treatment, for patients with advanced or metastatic hepatocellular carcinoma. The theoritical duration of the study is 5 years. In the scope of this study, each patient will have 2 years of treatment and 2 years of foloow-up from their enrollment date.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Federation Francophone de Cancerologie Digestive

Treatments:

Antibodies, Monoclonal
Atezolizumab
Bevacizumab
Ipilimumab